ANGPT1 and prostate carcinoma: Trebananib, the most clinically advanced inhibitor of both Ang1 and Ang2, is currently being tested in three phase III studies in advanced ovarian cancer (TRINOVA-1, NCT01204749; TRINOVA-2, NCT01281254; TRINOVA-3, NCT01493505), as well as in phase II studies of breast (NCT00511459, NCT01042379) and prostate cancer (NCT01553188).